Ambien CR Gets FDA Approval; Launch Expected In Mid-September
This article was originally published in The Pink Sheet Daily
Executive Summary
Sanofi-Aventis' follow-on sleep agent is indicated for insomnia characterized by difficulties in sleep onset or maintenance.
You may also be interested in...
Sanofi-Aventis Rebates Aim To Accelerate Switch To Ambien CR
Firm is offering concessions to U.S. healthcare providers to switch patients to the extended-release formulation.
Sanofi-Aventis Rebates Aim To Accelerate Switch To Ambien CR
Firm is offering concessions to U.S. healthcare providers to switch patients to the extended-release formulation.
Ambien Publicity Sets The Whole Class On Snooze, Sanofi Says
Despite an initial dip in sales during Q1 stemming from a class action suit, Sanofi-Aventis says growth of the insomnia drug returned to previous levels.